Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025

Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme

Dr Mandaviya delivers keynote address at 5th Foundation Day of National Cancer Institute, AIIMS Jhajjar

Launches collaborative centre for translational research in head and neck cancer

Health Minister Mandaviya delivers keynote address 2nd Voice of Global South Summit 2023

Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure

Merck’s Phase 3 Keynote- A18 trial met PFS in patients with advanced cervical cancer

KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

Keytruda plus Trodelvy reduced risk of disease progression by 35% V/s Keytruda plus cchemothrapy in first-line PD-L1+ TNBC

First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC

India reaffirms commitment to global pharmaceutical standardization and regulatory convergence: Anupriya Patel

International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization

SVU to organise International Conference on Clinical Translation of Biomaterial-based Therapeutics and Devices on 6-7 Feb, 2025

The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”

CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance

This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions

Merck receives positive EU CHMP opinion for pembrolizumab plus chemotherapy as first-line treatment for unresectable non-epithelioid MPM

Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial